Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Chronic bronchitis. Choosing the optimal treatment

D E Griffith1, R S Kronenberg

  • 1Department of Medicine, University of Texas Health Center, Tyler 75710.

Postgraduate Medicine
|December 1, 1993
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

When is a non-tuberculous mycobacterial infection a pulmonary disease?

The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease·2016
Same author

Pulmonary non-tuberculous mycobacterial infections.

The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease·2010
Same author

Treatment of isoniazid-resistant tuberculosis in southeastern Texas.

Chest·2001
Same author

The effect of azithromycin and clarithromycin on ex vivo interleukin-8 (IL-8) release from whole blood and IL-8 production by human alveolar macrophages.

The Journal of antimicrobial chemotherapy·2001
Same author

T cells enhance production of IL-18 by monocytes in response to an intracellular pathogen.

Journal of immunology (Baltimore, Md. : 1950)·2001
Same author

Azithromycin-containing regimens for treatment of Mycobacterium avium complex lung disease.

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America·2001

Quitting smoking is crucial for chronic bronchitis symptom relief and lung function. While challenging, combining smoking cessation with medications like ipratropium bromide offers the best patient outcomes.

Area of Science:

  • Pulmonology
  • Respiratory Medicine
  • Pharmacology

Background:

  • Chronic bronchitis management requires effective symptom relief and pulmonary function preservation.
  • Cigarette smoking cessation is paramount, yet patient outcomes are often suboptimal despite intensive programs.

Purpose of the Study:

  • To review the importance of smoking cessation in chronic bronchitis.
  • To evaluate the efficacy and safety of pharmacologic interventions for chronic bronchitis.

Main Methods:

  • Review of current therapeutic strategies for chronic bronchitis.
  • Analysis of the role of bronchodilators and anti-inflammatory agents.
  • Emphasis on smoking cessation programs and pharmacologic support.

Main Results:

Related Experiment Videos

  • Smoking cessation is the most critical intervention for chronic bronchitis.
  • Ipratropium bromide (Atrovent) is recommended as the initial bronchodilator therapy due to its effectiveness and safety profile.
  • Inhaled corticosteroids may benefit select patients, but their role requires further clarification.

Conclusions:

  • Smoking cessation, coupled with appropriate pharmacologic treatment, significantly improves chronic bronchitis symptoms and lung function.
  • Judicious use of bronchodilators and consideration of anti-inflammatory drugs are key components of chronic bronchitis management.